The Association of Cardiovascular Disease (CVD) with Progression of Advanced Fibrosis Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Objective

Advanced fibrosis is the best predictor of future severe liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Our study aims to determine the association between cardiovascular disease (CVD) with time to a high-risk Fibrosis-4 Index (FIB-4) in patients with low-risk MASLD.